Game Changers: Ocular Therapeutix

We are constantly impressed and amazed by the groundbreaking discoveries and research efforts in the life sciences community. In honor of this great work, we highlight game-changing innovators and innovations each month here at MassBioHQ.

MassBio Member Company Ocular Therapeutix’s CEO Amar Sawhney recently shared with the world how his company is changing the paradigm of eye care. Just this week, Ocular Therapeutix launched their Phase 2 trial of their new drug delivery “punctum plugs.”

Here is Amar Sawhney’s interview with Mass Device as part of their Disruptors series:

Ocular developed the punctum plugs to treat patients with ocular hypertension (abnormal pressure in the eye) and glaucoma.

“When I talk to glaucoma patients who are not able or don’t remember to take their drops, we may think it’s a simple thing but they can’t do it. And there is an art to taking drops and there is a real need.” -Amar Sawnhey, CEO of Ocular Therapeutix Inc.

By eliminating self-administered eye drops from the equation, Ocular will be able to ensure patients receive their prescribed treatment in its entirety. This is especially beneficial to patients managing a long-term diseases such as glaucoma, which does not cause pain, but without regular treatment can result in blindness.

Read more here: MHT 8/21/12